Torthaí cuardaigh - Tai‐Tsang Chen

  • 1 - 13 toradh as 13 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    Statistical issues and challenges in immuno-oncology

    Statistical issues and challenges in immuno-oncology de réir Tai‐Tsang Chen

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors

    Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors de réir Tai‐Tsang Chen

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study

    Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study de réir Neil P. Shah, Wang, Amit Roy, Andreas Hochhaus, Kantarjian, Tai‐Tsang Chen

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

    Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma de réir Feng Yan, Amit Roy, Eric Masson, Tai‐Tsang Chen, Rachel Humphrey, Jeffrey S. Weber

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)

    Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20) de réir David F. McDermott, John B.A.G. Haanen, Tai‐Tsang Chen, Paul Lorigan, Steven O’Day

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

    Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia de réir Alfonso Quintás-Cardama, Jorge E. Cortés, Susan O’Brien, Farhad Ravandi, Gautam Borthakur, David Liu, Eric Bleickardt, Tai‐Tsang Chen, Hagop M. Kantarjian

    Foilsithe / Cruthaithe 2009
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

    Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma de réir Dirk Schadendorf, F. Stephen Hodi, Caroline Robert, Jeffrey S. Weber, Kim Margolin, Omid Hamid, Debra A. Patt, Tai‐Tsang Chen, David M. Berman, Jedd D. Wolchok

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

    Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial de réir Michele Maio, Jean‐Jacques Grob, Steinar Aamdal, Igor Bondarenko, Caroline Robert, L. Thomas, Claus Garbe, Vanna Chiarion‐Sileni, Alessandro Testori, Tai‐Tsang Chen, Marina Tschaika, Jedd D. Wolchok

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective

    Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective de réir Neil Lineberry, Jesse A. Berlin, Bernadette Mansi, Susan Glasser, Michael Berkwits, Christian Klem, Ananya Bhattacharya, Leslie Citrome, Robert E. Enck, John Fletcher, Daniel G. Haller, Tai‐Tsang Chen, Christine Lainé

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy

    Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy de réir Stefan Suciu, Alexander M.M. Eggermont, Paul Lorigan, John M. Kirkwood, Svetomir N. Markovic, Claus Garbe, David Cameron, Srividya Kotapati, Tai‐Tsang Chen, Keith Wheatley, Natalie Ives, Gaetan de Schaetzen, Achmad Efendi, Marc Buyse

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

    Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias de réir Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian, Nicholas J. Donato, John Nicoll, Ron Paquette, Jorge E. Cortés, Susan O’Brien, Claude Nicaise, Eric Bleickardt, M. Anne Blackwood-Chirchir, Vishwanath R. Iyer, Tai‐Tsang Chen, Fei Huang, Arthur P. DeCillis, Charles L. Sawyers

    Foilsithe / Cruthaithe 2006
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358

    Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358 de réir R. Wendel Naumann, Ana Oaknin, Tim Meyer, José M. López-Picazo, Christopher D. Lao, Yu Jeong Bang, Valentina Boni, William H. Sharfman, J.C. Park, Lot A. Devriese, Kenichi Harano, Christine H. Chung, Suzanne L. Topalian, Kam Zaki, Tai‐Tsang Chen, Junchen Gu, B. Li, Adam Barrows, Andrea Horváth, Kathleen N. Moore

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma de réir Caroline Robert, L. Thomas, Igor Bondarenko, Steven O’Day, Jeffrey S. Weber, Claus Garbe, Célèste Lebbé, Jean‐François Baurain, Alessandro Testori, Jean‐Jacques Grob, Neville Davidson, Jon Richards, Michele Maio, Axel Hauschild, Wilson H. Miller, Pere Gascón, Michal Lotem, Kaan Harmankaya, Ramy Ibrahim, Stephen Francis, Tai‐Tsang Chen, Rachel Humphrey, Axel Hoos, Jedd D. Wolchok

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: